Can prostate cancer be NICE?
Journal
Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
09
05
2019
accepted:
14
06
2019
pubmed:
22
7
2019
medline:
9
6
2020
entrez:
21
7
2019
Statut:
ppublish
Résumé
On 9 May 2019, the National Institute for Health and Care Excellence (NICE) published its updated UK guidance on prostate cancer. The publication is the culmination of a 3 year process. It is an evidence-based, carefully crafted, comprehensive "book" to compliment the pre-existing 2014 guidance. It was born from new evidence on aspects of prostate cancer treatment and, most relevant for this special edition, diagnosis. This article provides a "behind-the-scenes" on how NICE operates, using the guideline as a case study. The piece sets out to demystify this august governance body's processes: from the decision to update the existing guidance, through the scoping and discussion stages to the principles and policies that shaped the whole process. This provides the backdrop to the second half of the article wherein the 85 page guideline is condensed in to a few highly pertinent recommendations. The areas that sparked the most debate during the committee's 24-month lifespan are highlighted, finishing by asking the UK radiology community: where do we go next in this new era of multiparametric magnetic resonance imaging first?
Identifiants
pubmed: 31324338
pii: S0009-9260(19)30299-5
doi: 10.1016/j.crad.2019.06.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
823-830Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.